NCT05764265View on ClinicalTrials.gov

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

April 26, 2024

Study Completion Date

May 14, 2024

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

LTP001

LTP001 will be administered orally once daily in the morning

Trial Locations (12)

28041

Novartis Investigative Site, Madrid

29010

Novartis Investigative Site, Málaga

69120

Novartis Investigative Site, Heidelberg

85206

Pulmonary Associates PA ., Mesa

C1025ABI

Novartis Investigative Site, Caba

01307

Novartis Investigative Site, Dresden

1081 HV

Novartis Investigative Site, Amsterdam

31 202

Novartis Investigative Site, Krakow

91-347

Novartis Investigative Site, Lodz

50-556

Novartis Investigative Site, Wroclaw

08036

Novartis Investigative Site, Barcelona

S10 2JF

Novartis Investigative Site, Sheffield

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY